The drug regulator has again declined to approve hypertension treatment Thelin, claiming that the drug is not effective enough and that a new study is needed before the drug could be reconsidered for approval, biotech firm Encysive Pharmaceuticals said Thursday. Encysive maintains that it has addressed the FDA's queries in its previous letter to the company.

Full Story:

Related Summaries